Genmab and AbbVie present positive topline data from cancer drug trial in new indication
On Wednesday, Genmab presented a set of promising data from an early study of its drug candidate, epcoritamab, as a third-line treatment for follicular lymphoma (FL).
In top-line data from a Phase I/II study, the results show an overall response rate (ORR) of 82%, which is higher than the predetermined endpoint.
At the same time, Genmab reports that the observed median duration of response (DOR) was not reached. Genmab’s CEO, Jan van de Winkel, describes the results as encouraging, and Genmab, along with partnering AbbVie, will now discuss the next steps with global regulatory authorities.
Previously, Jan van de Winkel has stated that he hopes Genmab can submit a registration application for epcoritamab as a third-line treatment for follicular lymphoma during the course of this year.
Epcoritamab was approved in the US earlier this year as a third-line treatment for diffuse large B-cell lymphoma. The drug is marketed under the name Epkinly.
Related articles
Genmab's epcoritamab added to cancer guidelines
For subscribers
